URGN
UroGen Pharma Ltd.
NASDAQ · USHealthcareBiotechnology
$41.12+2.21%
Price as of Jul 20, 2026
URGN financials
UroGen Pharma Ltd. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M |
| Cost of revenue | $12.4M | $8.9M | $9.4M | $7.7M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M |
| Operating expenses | $222.2M | $178.3M | $138.9M | $135.7M |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M |
| EBITDA | -$135.7M | -$95.4M | -$60.4M | -$76.2M |
| Basic EPS | $-3.19 | $-2.96 | $-3.55 | $-4.79 |
| Diluted EPS | $-3.19 | $-2.96 | $-3.55 | $-4.79 |
| Balance sheet | ||||
| Cash & equivalents | $110.7M | $172.0M | $95.0M | $55.4M |
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M |
| Stockholders’ equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M |
| Total debt | $128.3M | $123.4M | $99.4M | $99.1M |
| Net debt | $17.6M | -$48.6M | $4.4M | $43.7M |
| Cash flow | ||||
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M |
| Capital expenditure | -$289.0K | -$295.0K | -$194.0K | -$254.0K |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |